On Wednesday, January 6, several attorneys from Williams Kherkher will be lending their time and their efforts to help staff the HBA’s LegalLine.
LegalLine is a program sponsored by the Houston Bar Association that lets individuals throughout Harris County get legal advice over the phone from licensed attorneys. Harris County residents can call in on the first and third Wednesdays of the month between the hours of 5:00 pm and 9:00 pm for free legal assistance. Our team is proud to once again have the opportunity to help with such a worthy cause.
Kentucky New Era and SurfKY News reported that Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, agreed to a $15.5 million settlement on December 22. The case was a consumer protection lawsuit in Kentucky that accused Johnson & Johnson of falsely marketing the second-generation antipsychotic prescription drug Risperdal.
The Kentucky Consumer Protection lawsuit stated that the manufacturer of the antipsychotic drug did not inform consumers of its dangers and that the drug was marketed for purposes other than those ordered by the U.S. Food and Drug Administration. Attorney General Conway said, “Janssen and Johnson & Johnson put patients at risk when they marketed Risperdal without disclosing the drug’s known side effects.”
According to reports, Janssen is not allowed to promote Risperdal for purposes not approved by the FDA or for populations in which it is not approved. Kentucky required Janssen to openly discuss the risks of the drug in advertisements.
Risperdal spawned male breast growth lawsuits all over the country, and there are still many cases on trial. If you have suffered any adverse side effects while taking Risperdal, contact our lawyers at Williams Kherkher by calling (888) 220-0640 today to learn how we can help you.
In early 2014, an announcement by the U.S. Food and Drug Administration shocked medical communities after power morcellators were said to be a threat when used in certain surgeries. A power morcellator is an electric-powered medical device used to break down large tissues into smaller fragments so that they may be removed through small incisions. It is commonly used in the removal of the uterus (hysterectomy) or uterine fibroids (myomectomy).
After many years of research, the FDA found that morcellators could spread concealed cancerous tissues to different parts of the body. There have been lawsuits in which women have developed leiomyosarcoma after the use of power morcellators in surgical procedures. The lawsuits also accuse manufacturers and medical professionals of not disclosing the side effects of the product.
If you have been affected by the use of power morcellator, please bring your case to our esteemed lawyers at Williams Kherkher for help in pursuing compensation for negligent pharmaceutical manufacturers. Call us now at (888) 220-0640.
Janssen Pharmaceuticals Inc., a division of Johnson & Johnson, was ordered to pay a plaintiff $500,000 by a Philadelphia jury on December 11, according to news sources. Plaintiff Timothy Stange, who started taking the anti-psychotic drug Risperdal when he was 11, was awarded in the verdict after he said that the pharmaceutical company did not warn him of the side effects associated with the drug.
Stange was prescribed Risperdal to control his Tourette syndrome, but he developed gynecomastia during the three years he spent on the medication. Gynecomastia is a condition in which male breasts become enlarged; it has been cited as a side effect in many Risperdal lawsuits throughout the country.
This is the first Risperdal case to result in a settlement of less than $1 million, and Stange’s lawyer stated that the effect of the gynecomastia was “modest,” as it mostly affected his social life by causing the young boy humiliation.
If you have developed gynecomastia after taking Risperdal, please contact our qualified pharmaceutical defect attorneys at Williams Kherkher by calling us today at (888) 220-0640.
According to the Sarcoma Foundation of America (SFA), uterine leiomyosarcoma (LMS) is a type of rare tumor, and only about six women out of a million are diagnosed in the United States every year. Most uterine LMS are diagnosed after a hysterectomy or myomectomy. While it is almost impossible to diagnose LMS before a surgery, an MRI paired with a blood test for serum lactic dehydrogenase (LDH) may result in an accurate diagnosis.
Uterine LMS is treated with surgery, and, according to statistics from the SFA, this treatment prevents the tumor from spreading beyond the uterus in 75% of the patients. Unfortunately, LMS is aggressive; there is only a 50% chance of survival within 5 years for people whose tumor is only in the uterus.
The use of power morcellators in surgeries allegedly metastasizes cancerous cells that become leiomyosarcoma. If you think you have suffered as a result of a power morcellator, speak with our lawyers at Williams Kherkher to begin building your product liability case. Call us today at (888) 220-0640.
This Christmas, John Eddie Williams and his wife, Sheridan, once again were proud to donate to the Goodfellows Program, a charitable organization that provides Christmas presents to nearly 50,000 underprivileged children. Click here to read a feature in the Houston Chronicle about the Williams’ donation.
The enlargement of the glandular tissue of the male breast is called gynecomastia. This condition often occurs as a result of a hormonal imbalance in the body, especially when the male body has more estrogen (female hormone) than androgen (male hormone).
Gynecomastia is commonly associated with other medical problems such as chronic kidney failure, cirrhosis of the liver, and hyperthyroidism. One prominent cause of gynecomastia may be the abuse of drugs and several medications.
The anti-psychotic drug Risperdal, manufactured by Johnson & Johnson, has spawned many lawsuits in which gynecomastia was cited as a side effect. Research has also linked this drug to the condition, and the manufacturer has listed gynecomastia as a side effect on the prescription packaging.
If you have been affected by serious side effects of a drug you should have been able to trust, the legal team at Williams Kherkher is prepared to represent you as you seek justice and compensation. Call us today at (888) 220-0640 to learn about the services we offer.
Four people were injured this afternoon after an explosion occurred at an industrial plant near Humble, TX. According to authorities, the explosion happened near 1:00 pm at Moore Rod and Pipe when a machine used to melt plastic in order to make pipes developed a blockage.
When four workers attempted to fix the clog, pressure accumulated inside the machine, resulting in the explosion. As a result, hot plastic that could have been as hot as 550 degrees flew at the workers, causing severe burns in some victims.
While one worker was treated and released at the plant, two of those injured remain in critical condition and a fourth in good condition. Authorities reported that at least one of the injured plant workers was taken to the Texas Medical Center and Memorial Hermann Hospital to receive treatment for their injuries.
FoxCarolina.com reported on November 24 that yet another power morcellator lawsuit was filed against a known manufacturer of the device over the metastasizing of a New York woman’s cancer. The lawsuit stated that the device was used in the plaintiff’s laparoscopic supracervical hysterectomy and bilateral salpingectomy procedure for uterine fibroid treatment.
This specific lawsuit states that the woman was tested for cancer before her procedure and the results came back negative. However, she was diagnosed with advanced leiomyosarcoma after her surgery.
The 43-year-old plaintiff, aware that her cancer was fatal, recorded testimony before passing away. She succumbed to her illness last September 2015. The lawsuit is now being handled by the plaintiff’s family.
Newsweek has recently reported that a group of gynecologists, oncologists, and women’s health experts have challenged the U.S. Food and Drug Administration’s warning notice on the use of power morcellators in uterine fibroid removal.
The physicians claimed that prohibiting the use of the electromechanical morcellator will just precipitate the use of more invasive and riskier alternative procedures and will pose more risks to the patient. The doctors issued an open letter to the FDA challenging the officials to reverse their decision to stop the use of the morcellator.
Power morcellators spawned lawsuits in recent years alleging that the device spreads uterine fibroids during surgical procedures which eventually become cancerous. The lawsuits involve mostly women, stating that they were diagnosed with leiomyosarcoma, a rare form of female cancer, after the use of morcellators.
If you have been negatively affected by the use of a power morcellator during routine surgery, the attorneys at Williams Kherkher may be able to help you pursue compensation for your undue suffering. Call us today at (888) 220-0640 to discuss your case.
« Previous 1 … 5 6 7 8 9 … 40 Next »